Populations | Phase 1 | Phase 2 | Approved | Current Status |
---|---|---|---|---|
Advanced Malignant PEComa AMPECT Clinical Trial | Single Agent | First FDA approved therapy for advanced malignant PEComa | ||
Pan-Tumor TSC1/TSC2 Inactivating Alterations | TSC1 Arm, Single Agent | Registration directed tumor-agnostic pivotal study in nab-sirolimus with arms for TSC1 and TSC2 inactivating alterations; open for enrollment
| ||
Pan-Tumor TSC1/TSC2 Inactivating Alterations | TSC2 Arm, Single Agent | Registration directed tumor-agnostic pivotal study in nab-sirolimus with arms for TSC1 and TSC2 inactivating alterations; open for enrollment
| ||
Advanced or recurrent endometrial cancer | nab-sirolimus + letrozole | Trial combining nab-sirolimus with letrozole for patients with endometrioid-type endometrial carcinoma; trial initiation in 4Q 2023
| ||
Neuroendocrine tumors (NETs) | Single Agent | Utilizing nab-sirolimus as a monotherapy in neuroendocrine tumors; trial initiation in 4Q 2023
| ||
Advanced solid tumors or NSCLC with KRASG12C mutation | nab-sirolimus | Ongoing collaboration with Currently open for enrollment |
Drug | Stage | Current Status | Advanced Malignant PEComa AMPECT Clinical Trial Single Agent |
Approved | First FDA approved therapy for advanced malignant PEComa |
---|---|---|
Pan-Tumor TSC1/TSC2 Inactivating Alterations TSC1 Arm, Single Agent | Phase 2 | Registration directed tumor-agnostic pivotal study in nab-sirolimus with arms for TSC1 and TSC2 inactivating alterations; open for enrollment
|
Pan-Tumor TSC1/TSC2 Inactivating Alterations TSC2 Arm, Single Agent | Phase 2 | Registration directed tumor-agnostic pivotal study in nab-sirolimus with arms for TSC1 and TSC2 inactivating alterations; open for enrollment
|
Advanced or recurrent endometrial cancer nab-sirolimus + letrozole | Phase 2 | Trial combining nab-sirolimus with letrozole for patients with endometrioid-type endometrial carcinoma; trial initiation in 4Q 2023
|
Neuroendocrine tumors (NETs) Single Agent | Phase 2 | Utilizing nab-sirolimus as a monotherapy in neuroendocrine tumors; trial initiation in 4Q 2023
|
Advanced solid tumors or NSCLC with KRASG12C mutation
nab-sirolimus + adagrasib |
Phase 1 | Ongoing collaboration with Currently open for enrollment |